The Latest Cardiac and Vascular News
BRADENTON, Fla.–(BUSINESS WIRE)–PaceMate™, the leading digital technology company in healthcare data management, is pleased to announce the appointment of seven cardiac electrophysiologist professionals as members of the company’s medical advisory board. As PaceMate™ continues forward in its mission to advance efficient digital healthcare solutions through innovative technology and its compassion-driven […]
– Operating loss decreased vs. Q1 2020 – Net loss increased vs. Q1 2020 – ZanthoSyn® revenues decreased vs. Q1 2020 – Company pursuing multiple funding opportunities HONOLULU, May 14, 2021 /PRNewswire/ — Cardax, Inc. (OTCQB:CDXI) reported its Q1 2021 results. Highlights: Financial Results. Operating loss decreased from $906,031 in Q1 2020 to $771,312 in Q1 2021 […]
WARRINGTON, Pa., May 13, 2021 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the first quarter ended March 31, 2021 and provided key business updates. Key Business and Financial Updates Expanded the participating […]
SAN CARLOS, Calif., May 13, 2021 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular and pulmonary cell based therapies, today reported financial results for the first quarter of 2021 and filed its quarterly report on Form 10-Q for the three months ended March […]
– Doubled the market opportunity for Treprostinil Injection by adding subcutaneous delivery – Resubmitted New Drug Application for LIQ861 (treprostinil) Inhalation Powder – Improved financial position with private placement and access to new credit facility – Company to host webcast and conference call today at 8:30 a.m. ET MORRISVILLE, N.C., May […]
CARLSBAD, Calif., May 12, 2021 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the first quarter of 2021. Recent Highlights: Reported revenue of $3.6 million in the […]
Topline data from Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 anticipated in the third quarter of 2021 WESTMINSTER, Colo., May 11, 2021 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today […]
FREEDOM clinical study on track for topline results in Q3 2021 Ended Q1 with cash, cash equivalents, restricted cash and investments of $96.5 million BURLINGTON, Mass., May 12, 2021 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to […]
TEL AVIV, Israel, May 12, 2021 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced it has appointed seasoned marketing executive Kathryn (Katie) Arnold to its Board of Directors. […]
BASKING RIDGE, N.J., May 12, 2021 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that it has received $1.4 million in non-dilutive funding as an approved participant of the […]
